Skip to main content

Mirum Pharmaceuticals, Inc.

corporate_fare Company Profile

Mirum Pharmaceuticals, Inc.

MIRM·NASDAQ·Life Sciences·CIK 0001759425

We are a biopharmaceutical company focused on treating rare diseases. We have three approved medicines: LIVMARLI® (maralixibat), CHOLBAM® (cholic acid) capsules, and CTEXLI® (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor. It is approved for cholestatic pruritus in patients with Alagille syndrome (ALGS) in the U.S., the European Union (EU), and various other countries. Livmarli is also approved for cholestatic pruritus in patients with progressive familial intrahepatic cholestasis (PFIC) in the U.S., Canada, and Japan, and for the treatment of PFIC in the EU. We market Livmarli in the U.S., Canada, and certain European countries through our commercial team and have license and distribution agreements for other countries. We are also conducting the EXPAND study to add indications for Livmarli for cholestatic pruritus due to other rare conditions. In August 2023, we acquired assets from Travere Therapeutics, Inc. related to the development, manufacture, and commercialization of chenodiol and Cholbam (also known as Kolbam). The U.S. Food and Drug Administration (FDA) approved Cholbam in March 2015 as the first FDA-approved treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder (PBD-ZSD). Chenodiol is the standard of care for cerebrotendinous xanthomatosis (CTX) in the U.S. and was commercialized as Chenodal. We submitted a New Drug Application (NDA) for chenodiol for CTX in 2024 and received FDA approval for the treatment of adults with CTX in February 2025.

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 30 items for MIRM at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Mirum Pharmaceuticals Reports Positive Phase 2b Results for Brelovitug in Chronic Hepatitis Delta Virus
  • Mirum Amends 8-K to Detail Bluejay Acquisition Financials and $260M PIPE Offering
  • Mirum Pharmaceuticals Completes Phase 3 Enrollment for Livmarli in Rare Liver Diseases; Topline Data Expected Q4 2026
  • Shelf Registration Filed for Resale of 8.96M Shares by Selling Stockholders from Recent Acquisition and Private Placements
  • Mirum Pharmaceuticals Reports Strong 2025 Financials, Expands Pipeline with Bluejay Acquisition, and Defends Key Patents

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$521.31M
Net Income
-$23.36M
Diluted EPS
-$0.47
Op. Cash Flow
$55.83M
Free Cash Flow
$54.87M
Gross Profit
$421.07M
Operating Income
-$22.14M
Cash & Equivalents
$296.68M
Debt / Equity
0.00×
Net Margin
-4.5%
Shares Outstanding
51.9M sh
Source: 10-K · filed 2026-02-25 · accession 0001759425-26-000013
$96.13
52-week range · as of 2026-11-10 $63.23 – $130
Market cap
$6.28B
Volume
1.1M (1.6× avg)
3-mo avg 647.8K
Live data · 2026-11-22 12:49 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed MIRM - Filings & News (Page 2)

MIRM
Apr 27, 2026, 8:07 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $92.69
Real-time Price: $96.13 info
Change: +$3.44 (+4%) info
Market Cap: $6.276B info
MIRM
Apr 08, 2026, 4:13 PM EDT
Filing Type: 8-K/A
Importance Score:
8
Price at Filing: $97.95
Real-time Price: $96.13 info
Change: -$1.82 (-2%) info
Market Cap: $6.276B info
MIRM
Mar 16, 2026, 8:10 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $90.63
Real-time Price: $96.13 info
Change: +$5.50 (+6%) info
Market Cap: $6.276B info
MIRM
Feb 25, 2026, 5:14 PM EST
Filing Type: S-3ASR
Importance Score:
8
Price at Filing: $104.04
Real-time Price: $96.13 info
Change: -$7.91 (-8%) info
Market Cap: $6.276B info
MIRM
Feb 25, 2026, 4:28 PM EST
Filing Type: 10-K
Importance Score:
9
Price at Filing: $104.04
Real-time Price: $96.13 info
Change: -$7.91 (-8%) info
Market Cap: $6.276B info
MIRM
Feb 25, 2026, 4:03 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $108.62
Real-time Price: $96.13 info
Change: -$12.49 (-11%) info
Market Cap: $6.276B info
MIRM
Jan 27, 2026, 4:14 PM EST
Filing Type: 4
Importance Score:
7
Price at Filing: $99.27
Real-time Price: $96.13 info
Change: -$3.14 (-3%) info
Market Cap: $6.276B info
MIRM
Jan 27, 2026, 4:12 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $99.27
Real-time Price: $96.13 info
Change: -$3.14 (-3%) info
Market Cap: $6.276B info
MIRM
Jan 26, 2026, 4:10 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $96.92
Real-time Price: $96.13 info
Change: -$0.790 (-0.82%) info
Market Cap: $6.276B info
MIRM
Jan 12, 2026, 8:40 AM EST
Filing Type: 8-K
Importance Score:
9
Price at Filing: $86.57
Real-time Price: $96.13 info
Change: +$9.56 (+11%) info
Market Cap: $6.276B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets